Medicine
Inflammatory Bowel Disease and Risk of Thromboembolism
Quick fact
People with IBD have a 2 to 3 times higher risk of developing blood clots (venous thromboembolism) compared to the general population, and this risk can be particularly elevated during flare-ups and when hospitalised.
Why this is interesting
You might assume that a disease of the gut only causes digestive problems. So why are people with inflammatory bowel disease—like Crohn's disease and ulcerative colitis—at a significantly higher risk of developing dangerous blood clots?
Read the full explanation
Understanding Inflammatory Bowel Disease and Risk of Thromboembolism
Think of your body as a complex highway system. The immune system is the maintenance crew, fighting off infections. In inflammatory bowel disease (IBD), this crew goes on overdrive, attacking the digestive tract and causing inflammation. This chronic inflammation doesn't stay only in the intestines—it triggers widespread changes throughout the body, including the blood. Blood is more likely to clot when there's inflammation because the body's balance between clotting and bleeding is disturbed. Imagine that inside the blood there are tiny workers: some build clots (like emergency roadblocks), and others break them down (like demolition crews). When inflammation is present, the builders are called to work more often, and the demolition crew is inhibited, so clots can form more easily. This can lead to conditions like deep vein thrombosis (blood clot in the leg) or pulmonary embolism (blood clot that travels to the lungs), which can be life-threatening. The risk is particularly high during active flares of the disease, when inflammation is at its peak, and also when a person is hospitalised and less mobile, which further slows blood flow.
A deeper explanation
The mechanism linking IBD to thromboembolism is fundamentally a state of hypercoagulability driven by chronic inflammation. In spite of being a localised disease, IBD is associated with systemic inflammatory responses. Chronic inflammation causes an increase in pro-inflammatory cytokines, such as tumour necrosis factor-alpha, which have several pro-coagulant effects. They upregulate the expression of tissue factor on circulating cells and vascular endothelium, which activates the extrinsic coagulation pathway. Simultaneously, the natural anticoagulant systems become impaired: levels of protein C and protein S fall, and the antithrombin system can be overwhelmed. Moreover, fibrinolysis—the breakdown of clots—is suppressed, partly due to elevated levels of plasminogen activator inhibitor-1 (PAI-1). This combination tips the haemostatic balance towards excessive clotting. Enhanced platelet activation and aggregation also occur, contributing to a prothrombotic state. This aligns with Virchow's triad: inflammation causes endothelial damage (the vessel wall), the altered coagulation proteins cause hypercoagulability (the blood), and factors like hospitalisation, bed rest, or surgery cause stasis (the flow). The risk is measurable and dose-dependent with disease activity; patients with active IBD face a higher risk than those in remission. However, the presence of IBD alone, even in remission, still raises the baseline risk compared with the general population. Despite these clear mechanisms, studies show that many hospitalised IBD patients do not receive the recommended preventive anticoagulation, leading to preventable harm. Deepening the understanding of this mechanism highlights the need for vigilance and proper prophylaxis.